We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
Read MoreHide Full Article
Key Takeaways
Lilly's Mounjaro and Zepbound drove $27.6 billion in combined first-half 2026 sales.
AbbVie expects Skyrizi and Rinvoq sales to exceed $31 billion in 2026, with over 20% growth.
Lilly's stronger growth outlook and expanding obesity opportunity make it the better overall pick.
Eli Lilly (LLY - Free Report) and AbbVie (ABBV - Free Report) are leading U.S. drugmakers with established portfolios, blockbuster therapies, robust R&D pipelines, large market capitalizations and a strong global presence. Both have significant exposure to major therapeutic areas, including immunology, oncology and neuroscience. AbbVie has diversified into aesthetics and eye care, while Lilly has established a strong foothold in cardiometabolic health.
AbbVie’s growth has been driven largely by the success of its immunology portfolio, while Lilly’s Mounjaro and Zepbound have emerged as key growth drivers, strengthening its position in the fast-growing cardiometabolic market.
Both companies are delivering solid revenues and profits and have promising growth prospects. But with different growth drivers, pipelines and challenges, which stock is the better investment option today? Let’s compare their fundamentals, growth outlook and key risks to make an informed choice.
The Case for Lilly Stock
Lilly has seen extraordinary momentum in its cardiometabolic franchise. Its blockbuster drugs, Mounjaro for type II diabetes and Zepbound for obesity, have become some of the fastest-growing medicines in pharmaceutical history, gaining from enormous global demand for GLP-1 therapies. These therapies account for around 65% of the company’s total revenues and have become key top-line drivers for Lilly, with demand rising rapidly. In the first half of 2026, the drugs generated combined sales of $27.6 billion.
Lilly’s newly launched once-daily oral GLP-1 pill, Foundayo (orforglipron), for treating obesity, can prove to be a commercial game-changer for Lilly. Oral pills will be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Zepbound and rival Novo Nordisk’s (NVO - Free Report) Wegovy. The launch uptake for Foundayo has been encouraging as Lilly expands physician engagement and direct-to-consumer promotion in the United States.
To maintain leadership in the GLP-1 market, Lilly is developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates. Retatrutide is one of Lilly’s most important late-stage pipeline candidates, targeting GLP-1, GIP and glucagon pathways and potentially delivering greater weight loss and broader metabolic benefits than current therapies. With late-stage studies spanning obesity, type II diabetes, obstructive sleep apnea (OSA) and other indications, Lilly plans to seek FDA approval in the first quarter of 2027, potentially creating another multibillion-dollar growth driver.
Lilly’s growth story is increasingly diversified beyond its GLP-1 franchise, with newer therapies such as Omvoh, Jaypirca, Ebglyss, Kisunla and Inluriyo gaining traction across multiple therapeutic areas. These products are becoming meaningful growth contributors.
The company has also embarked on an aggressive M&A spree in the past couple of years, acquiring biotech companies across oncology, neuroscience, cardiovascular disease, gene editing, inflammation, cell therapy and vaccines to diversify its long-term growth drivers beyond GLP-1 therapies. The company has announced more than $20 billion in biotech deals this year.
Lilly has its share of problems. Prices of most of Lilly’s products are declining in the United States. Price is expected to continue to be a drag on top-line growth in the low to mid-teens percentage in 2026. Rising competition in the GLP-1 diabetes/obesity market is a key headwind. Also, sales of late-life cycle products like Trulicity, Taltz and Verzenio are expected to be flat to down in 2026.
The Case for AbbVie Stock
AbbVie has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, which once generated more than 50% of its total revenues. It has accomplished this by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion. It recorded $14.6 billion in sales in the first half. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026.
However, AbbVie expects a low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026 and over the next few years. Moreover, the launch of J&J’s (JNJ - Free Report) new oral pill for moderate-to-severe plaque psoriasis, Icotyde, has increased competitive pressure for Skyrizi, which can impact the product’s prescription trends. However, AbbVie seems confident that it can navigate competition from J&J’s Icotyde.
AbbVie is also benefiting from strong momentum outside immunology. The oncology franchise remains anchored by Venclexta and Elahere, while the neuroscience portfolio is also contributing to top-line growth, driven by higher sales of Botox Therapeutic, depression drug Vraylar, newer migraine drugs Ubrelvy and Qulipta and new Parkinson’s disease drug Vyalev.
Like Lilly, AbbVie has been on an acquisition spree over the past couple of years to bolster the early-stage pipeline that should drive long-term growth. It is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience. The approximately $10.9 billion pending acquisition of Apogee Therapeutics is expected to strengthen its late-stage immunology pipeline.
AbbVie boasts a robust pipeline and expects important data readouts, regulatory submissions and approvals throughout the rest of 2026.
The company faces some near-term headwinds like Humira’s biosimilar erosion, slowdown in oncology sales and soft sales of its Aesthetics unit for the past couple of years due to continued macro challenges and economic headwinds.
How Do Estimates Compare for LLY & ABBV?
The Zacks Consensus Estimate for LLY’s 2026 sales and EPS implies a year-over-year increase of 35.4% and 48.4%, respectively. EPS estimates for 2026 and 2027 have risen over the past 30 days.
LLY Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for AbbVie’s 2026 sales and EPS implies a year-over-year increase of 10.5% and 40.6%, respectively. The EPS estimate for 2026 has declined from $14.19 to $14.06 over the past 30 days, while that for 2027 has declined from $16.19 to $16.16 over the same timeframe.
ABBV Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of LLY & ABBV
So far this year, LLY’s stock has risen 16.0% and AbbVie’s stock has risen 15.8%. The industry has risen 18.2% in the said time frame.
Image Source: Zacks Investment Research
AbbVie looks more attractive than Lilly from a valuation standpoint. Going by the price/earnings ratio, Lilly’s shares currently trade at 29.42 forward earnings, significantly higher than 19.50 for the industry. However, LLY currently trades lower than its 5-year mean of 34.57. AbbVie’s shares currently trade at 17.15 forward earnings, lower than the industry. ABBV shares, however, trade above the stock’s 5-year mean of 14.07.
Image Source: Zacks Investment Research
AbbVie’s dividend yield is 2.6%, while Lilly’s is around 0.6%.
AbbVie has successfully replaced much of the lost revenues from Humira with strong growth from Skyrizi and Rinvoq. AbbVie expects a year of robust growth in 2026. It expects total revenues to rise around 10% in 2026, backed mainly by significant momentum in immunology and neuroscience products, which are demonstrating significant growth and delivering share gains in growing markets. It expects high single-digit revenue growth through 2029. However, near-term profitability remains affected by acquired in-process research and development charges related to the Apogee acquisition.
Lilly remains one of the most compelling growth stories in the pharmaceutical industry, supported by its significant price appreciation, dominant position in the rapidly expanding obesity and diabetes markets, a diversified late-stage pipeline and strong financial performance. While the stock trades at a premium valuation after a remarkable multi-year rally, the company's long-term growth prospects remain among the strongest in the healthcare sector.
Given Lilly’s much stronger growth trajectory and expanding obesity opportunity, it is currently a better pick.
View the Zacks #1 Rank List
Image: Bigstock
LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?
Key Takeaways
Eli Lilly (LLY - Free Report) and AbbVie (ABBV - Free Report) are leading U.S. drugmakers with established portfolios, blockbuster therapies, robust R&D pipelines, large market capitalizations and a strong global presence. Both have significant exposure to major therapeutic areas, including immunology, oncology and neuroscience. AbbVie has diversified into aesthetics and eye care, while Lilly has established a strong foothold in cardiometabolic health.
AbbVie’s growth has been driven largely by the success of its immunology portfolio, while Lilly’s Mounjaro and Zepbound have emerged as key growth drivers, strengthening its position in the fast-growing cardiometabolic market.
Both companies are delivering solid revenues and profits and have promising growth prospects. But with different growth drivers, pipelines and challenges, which stock is the better investment option today? Let’s compare their fundamentals, growth outlook and key risks to make an informed choice.
The Case for Lilly Stock
Lilly has seen extraordinary momentum in its cardiometabolic franchise. Its blockbuster drugs, Mounjaro for type II diabetes and Zepbound for obesity, have become some of the fastest-growing medicines in pharmaceutical history, gaining from enormous global demand for GLP-1 therapies. These therapies account for around 65% of the company’s total revenues and have become key top-line drivers for Lilly, with demand rising rapidly. In the first half of 2026, the drugs generated combined sales of $27.6 billion.
Lilly’s newly launched once-daily oral GLP-1 pill, Foundayo (orforglipron), for treating obesity, can prove to be a commercial game-changer for Lilly. Oral pills will be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Zepbound and rival Novo Nordisk’s (NVO - Free Report) Wegovy. The launch uptake for Foundayo has been encouraging as Lilly expands physician engagement and direct-to-consumer promotion in the United States.
To maintain leadership in the GLP-1 market, Lilly is developing several next-generation, more powerful and more convenient GLP-1–based treatments, including oral options and multi-acting candidates. Retatrutide is one of Lilly’s most important late-stage pipeline candidates, targeting GLP-1, GIP and glucagon pathways and potentially delivering greater weight loss and broader metabolic benefits than current therapies. With late-stage studies spanning obesity, type II diabetes, obstructive sleep apnea (OSA) and other indications, Lilly plans to seek FDA approval in the first quarter of 2027, potentially creating another multibillion-dollar growth driver.
Lilly’s growth story is increasingly diversified beyond its GLP-1 franchise, with newer therapies such as Omvoh, Jaypirca, Ebglyss, Kisunla and Inluriyo gaining traction across multiple therapeutic areas. These products are becoming meaningful growth contributors.
The company has also embarked on an aggressive M&A spree in the past couple of years, acquiring biotech companies across oncology, neuroscience, cardiovascular disease, gene editing, inflammation, cell therapy and vaccines to diversify its long-term growth drivers beyond GLP-1 therapies. The company has announced more than $20 billion in biotech deals this year.
Lilly has its share of problems. Prices of most of Lilly’s products are declining in the United States. Price is expected to continue to be a drag on top-line growth in the low to mid-teens percentage in 2026. Rising competition in the GLP-1 diabetes/obesity market is a key headwind. Also, sales of late-life cycle products like Trulicity, Taltz and Verzenio are expected to be flat to down in 2026.
The Case for AbbVie Stock
AbbVie has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, which once generated more than 50% of its total revenues. It has accomplished this by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years.
In 2026, AbbVie expects combined Skyrizi and Rinvoq sales of more than $31 billion. It recorded $14.6 billion in sales in the first half. Combined, Skyrizi and Rinvoq are expected to deliver more than 20% growth in 2026.
However, AbbVie expects a low single-digit pricing headwind for both Skyrizi and Rinvoq in 2026 and over the next few years. Moreover, the launch of J&J’s (JNJ - Free Report) new oral pill for moderate-to-severe plaque psoriasis, Icotyde, has increased competitive pressure for Skyrizi, which can impact the product’s prescription trends. However, AbbVie seems confident that it can navigate competition from J&J’s Icotyde.
AbbVie is also benefiting from strong momentum outside immunology. The oncology franchise remains anchored by Venclexta and Elahere, while the neuroscience portfolio is also contributing to top-line growth, driven by higher sales of Botox Therapeutic, depression drug Vraylar, newer migraine drugs Ubrelvy and Qulipta and new Parkinson’s disease drug Vyalev.
Like Lilly, AbbVie has been on an acquisition spree over the past couple of years to bolster the early-stage pipeline that should drive long-term growth. It is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience. The approximately $10.9 billion pending acquisition of Apogee Therapeutics is expected to strengthen its late-stage immunology pipeline.
AbbVie boasts a robust pipeline and expects important data readouts, regulatory submissions and approvals throughout the rest of 2026.
The company faces some near-term headwinds like Humira’s biosimilar erosion, slowdown in oncology sales and soft sales of its Aesthetics unit for the past couple of years due to continued macro challenges and economic headwinds.
How Do Estimates Compare for LLY & ABBV?
The Zacks Consensus Estimate for LLY’s 2026 sales and EPS implies a year-over-year increase of 35.4% and 48.4%, respectively. EPS estimates for 2026 and 2027 have risen over the past 30 days.
LLY Estimate Movement
The Zacks Consensus Estimate for AbbVie’s 2026 sales and EPS implies a year-over-year increase of 10.5% and 40.6%, respectively. The EPS estimate for 2026 has declined from $14.19 to $14.06 over the past 30 days, while that for 2027 has declined from $16.19 to $16.16 over the same timeframe.
ABBV Estimate Movement
Price Performance and Valuation of LLY & ABBV
So far this year, LLY’s stock has risen 16.0% and AbbVie’s stock has risen 15.8%. The industry has risen 18.2% in the said time frame.
AbbVie looks more attractive than Lilly from a valuation standpoint. Going by the price/earnings ratio, Lilly’s shares currently trade at 29.42 forward earnings, significantly higher than 19.50 for the industry. However, LLY currently trades lower than its 5-year mean of 34.57. AbbVie’s shares currently trade at 17.15 forward earnings, lower than the industry. ABBV shares, however, trade above the stock’s 5-year mean of 14.07.
AbbVie’s dividend yield is 2.6%, while Lilly’s is around 0.6%.
LLY or ABBV: Which is a Better Pick?
AbbVie and Lilly have a Zacks Rank #3 (Hold) each, which makes choosing one stock a difficult task. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AbbVie has successfully replaced much of the lost revenues from Humira with strong growth from Skyrizi and Rinvoq. AbbVie expects a year of robust growth in 2026. It expects total revenues to rise around 10% in 2026, backed mainly by significant momentum in immunology and neuroscience products, which are demonstrating significant growth and delivering share gains in growing markets. It expects high single-digit revenue growth through 2029. However, near-term profitability remains affected by acquired in-process research and development charges related to the Apogee acquisition.
Lilly remains one of the most compelling growth stories in the pharmaceutical industry, supported by its significant price appreciation, dominant position in the rapidly expanding obesity and diabetes markets, a diversified late-stage pipeline and strong financial performance. While the stock trades at a premium valuation after a remarkable multi-year rally, the company's long-term growth prospects remain among the strongest in the healthcare sector.
Given Lilly’s much stronger growth trajectory and expanding obesity opportunity, it is currently a better pick.